In recent years, notable advances have been made in diagnosing and treating breast cancer. However, its recurrence continues ...

For patients with early-stage triple-negative breast cancer (TNBC), finishing chemotherapy and surgery should feel like the end of the hardest chapter. But for many, it marks the beginning of a ...

While radiation therapy is an effective tool to destroy cancer cells, a new study from Vanderbilt researchers suggests that in an aggressive form of breast cancer, it may also trigger a protective ...

Ultrasensitive circulating tumor DNA (ctDNA) testing may help identify women with triple-negative breast cancer who are at either a very high or very low risk for recurrence after surgery, new ...

A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National Cancer Centre Singapore, has demonstrated a significant breakthrough in ...

Precision DC: Personalized neoantigen dendritic cell vaccine pilot trial for high-risk triple-negative breast cancer after neoadjuvant therapy. This is an ASCO Meeting Abstract from the 2026 ASCO ...

While triple-negative breast cancer (TNBC) is generally an aggressive subtype, it is highly heterogeneous, with a subset of patients having a more favorable biology and high responsiveness to systemic ...

Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with ...

Patients facing advanced triple‑negative breast cancer (TNBC) know how unforgiving this disease can be, especially when immunotherapy isn’t an option. Now, following the Food and Drug Administration’s ...

This is read by an automated voice. Please report any issues or inconsistencies here. A study of 24,337 female patients found that COVID-19 is associated with a 2.47 hazard ratio for local breast ...